Stay updated on Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page changed from a 403 error screen to the ClinicalTrials.gov record for a Phase 2 metastatic melanoma study, including its eligibility criteria, treatment arms, outcomes, and study documents.
    Difference
    55%
    Check dated 2026-11-09T13:55:44.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T15:51:10.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The clinical trial record for a Phase 2 study of nivolumab with relatlimab or ipilimumab in metastatic melanoma is displayed, including its terminated status due to loss of funding and its study details. The record also includes results-related measures, eligibility criteria, and a study protocol document.
    Difference
    58%
    Check dated 2026-10-26T15:13:40.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the page remained a 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T14:51:45.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-12T16:12:39.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a generic header/footer, replacing the usual study details and indicating the record is temporarily inaccessible rather than content updates.
    Difference
    19%
    Check dated 2026-09-21T22:24:00.000Z thumbnail image

Stay in the know with updates to Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.